Nicholas J. Silvestri, MD, expects that the upcoming 2025 American Academy of Neurology Annual Meeting in San Diego will be an exciting event for the field of myasthenia gravis (MG), with anticipated discussions on new data and therapies. Recent years have seen multiple approvals in the MG space, and the meeting is expected to feature open-label extension data for agents like efgartigimod, rozanolixizumab, and complement-based therapies such as ravulizumab and eculizumab.
He also looks forward to discussions on new developments, including neonatal Fc receptor (FcRn) antagonists such as nipocalimab and batoclimab, and B-cell therapies such as inebilizumab, with a focus on long-term efficacy and safety for patients. Additionally, promising CAR T therapy programs for MG and real-world clinical experiences will be shared, making the meeting an exciting opportunity for further insights into the evolving landscape of MG treatments.
